Agenus presents clinical data on PD-1, CTLA-4 at ESMO 2018
Agenus presented updated clinical data on its lead CTLA-4 and PD-1 programs at the 2018 European Society for Medical Oncology Congress, in Munich, Germany. Data presented at ESMO is based on 76 patients treated with PD-1 as well as combination PD-1 and CTLA-4 regimens. Agenus' anti-PD-1 and CTLA-4 reveal clinical activity across multiple solid tumors, including breast and gynecologic cancers such as cervical and ovarian. Patients treated with AGEN2034 reveal a clinical benefit rate of 68% in evaluable patients with metastatic and/or locally advanced solid tumors, and in 3 of 7 evaluable patients with refractory cervical cancer. Data from combination AGEN2034 plus AGEN1884 show similar trends; early clinical benefit observed in 7 of 16 evaluable patients with ovarian, breast, and soft tissue sarcoma, including a durable response in a patient with ovarian cancer. Since the ESMO data cut-off, early evidence of clinical benefit was observed in patients with cervical cancer treated with combination AGEN2034 and AGEN1884.